VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

G. Palmieri; M. Perego; I. M. Baldini

VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

Translated title of the contribution: Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl

G. Palmieri, M. Perego, I. M. Baldini

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

Translated title of the contribution	Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl
Original language	Italian
Pages (from-to)	143-152
Number of pages	10
Journal	Gazzetta Medica Italiana
Volume	141
Issue number	4
Publication status	Published - 1982

ASJC Scopus subject areas

Medicine(all)

Access to Document

Fingerprint Dive into the research topics of 'Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl'. Together they form a unique fingerprint.

Cite this

@article{01122c093a2a471da3ee03a7ee10156f,

title = "VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL",

abstract = "A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.",

author = "G. Palmieri and M. Perego and Baldini, {I. M.}",

year = "1982",

language = "Italian",

volume = "141",

pages = "143--152",

journal = "Gazzetta Medica Italiana Archivio per le Scienze Mediche",

issn = "0393-3660",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "4",

}

TY - JOUR

T1 - VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

AU - Palmieri, G.

AU - Perego, M.

AU - Baldini, I. M.

PY - 1982

Y1 - 1982

N2 - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

AB - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

UR - http://www.scopus.com/inward/record.url?scp=0020324693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020324693&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0020324693

VL - 141

SP - 143

EP - 152

JO - Gazzetta Medica Italiana Archivio per le Scienze Mediche

JF - Gazzetta Medica Italiana Archivio per le Scienze Mediche

SN - 0393-3660

IS - 4

ER -